NRx Pharmaceuticals Inc. (NRXP)

AI Score

Unlock

1.77

-0.10 (-5.35%)

At close: Apr 04, 2025, 3:59 PM

1.82

2.57%

After-hours: Apr 04, 2025, 04:29 PM EDT

-5.35% (1D)

Bid	1.75
Market Cap	29.94M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
EPS (ttm)	-2.36
PE Ratio (ttm)	-0.75
Forward PE	-118.33
Analyst	Buy

Ask	2.07
Volume	177,443
Avg. Volume (20D)	642,378
Open	1.85
Previous Close	1.87
Day's Range	1.76 - 1.85
52-Week Range	1.10 - 6.01
Beta	1.41

About NRXP

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 4, 2017

Employees 2

Stock Exchange NASDAQ

Ticker Symbol NRXP

Website https://www.nrxpharma.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for NRXP stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 1651.41% from the latest price.

Stock Forecasts

Next Earnings Release

NRx Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+24.56%

NRx Pharmaceuticals shares are trading higher afte... Unlock content with Pro Subscription

2 months ago

+30.48%

NRX Pharmaceuticals shares are trading higher after the company announced it will acquire Dura Medical with HOPE Therapeutics. Additionally, the company signed a binding term sheet with HOPE with $27 million to fund further acquisitions and pharmaceutical operations.

News

1 week ago · zacks.com

Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now

NRx Pharmaceuticals (NRXP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul...

2 weeks ago · seekingalpha.com

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and ...

1 month ago · zacks.com

NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?

NRXP is expected to provide updates on its pipeline candidates being developed for treating central nervous system disorders when it reports fourth-quarter earnings release.